Sildenafil is a cornerstone treatment for persistent pulmonary hypertension of the newborn (PPHN), but sometimes additional therapies are needed. Inhaled nitric oxide (iNO) often complements sildenafil, improving oxygenation and pulmonary vascular resistance. Consider iNO particularly if sildenafil alone isn’t sufficient to achieve adequate oxygen saturation.
Extracorporeal membrane oxygenation (ECMO) provides life support by oxygenating and filtering blood outside the body when other treatments fail to improve oxygenation. This is a highly specialized procedure, utilized when PPHN is severe and life-threatening.
Surfactant replacement therapy may prove beneficial, especially in cases where respiratory distress syndrome coexists with PPHN. Surfactant improves lung function, aiding oxygen exchange and potentially reducing the severity of PPHN.
High-frequency oscillatory ventilation (HFOV) offers an alternative respiratory support strategy. HFOV delivers small tidal volumes at high frequency, reducing lung injury and improving gas exchange in infants with severe PPHN. Close monitoring of the infant’s response to therapy is paramount.
Careful patient selection is crucial. The best approach depends on the severity of PPHN, the infant’s overall health, and available resources. Consult with a neonatologist and a specialized team experienced in managing PPHN for the optimal treatment plan.
